Antineutrophil cytoplasmic antibodies in patients treated with methimazole: a prospective Brazilian study

Detalhes bibliográficos
Autor(a) principal: Andrade,Gabriela Costa
Data de Publicação: 2019
Outros Autores: Maia,Flavia Coimbra Pontes, Mourão,Gabriela Franco, Rosario,Pedro Weslley, Calsolari,Maria Regina
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Journal of Otorhinolaryngology
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1808-86942019000500636
Resumo: Abstract Introduction: The side effects of antithyroid drugs are well known. Antineutrophil cytoplasmic antibody-associated vasculitis is a severe adverse reaction. Most studies evaluating antineutrophil cytoplasmic antibodies related to antithyroid drugs have been carried out with patients treated with propylthiouracil, but less information is available for methimazole. Furthermore, most studies that investigated antineutrophil cytoplasmic antibodies related to antithyroid drugs were conducted on Asian populations. Objective: To evaluate the frequency of antineutrophil cytoplasmic antibodies and antineutrophil cytoplasmic antibodies-positive vasculitis in an adult population of Brazilian patients treated with methimazole. Methods: This was a prospective study. We evaluated patients ≥18 years with Graves’ disease who have been using methimazole for at least 6 months (Group A, n = 36); with Grave's disease who had been previously treated with methimazole but no longer used this medication for at least 6 months (Group B, n = 33), and with nodular disease who have been using methimazole for at least 6 months (Group C, n = 13). Results: ANCA were detected in 17 patients (20.7%). Four patients (4.9%) had a strong antineutrophil cytoplasmic antibodies-positive test. The frequency of antineutrophil cytoplasmic antibodies was similar in the groups. When Groups A and B were pooled and compared to Group C to evaluate the influence of Grave's disease, and when Groups A and C were pooled and compared to Group B to evaluate the influence of methimazole discontinuation, no difference was found in the frequency of antineutrophil cytoplasmic antibodies. No difference was observed in sex, age, etiology of hyperthyroidism, anti-TSH receptor antibodies, dose or time of methimazole use between patients with versus without antineutrophil cytoplasmic antibodies. The titers of these antibodies were not correlated with the dose or time of methimazole use. None of the antineutrophil cytoplasmic antibodies-positive patient had clinical event that could potentially result from vasculitis. Conclusion: This clinical study of a Brazilian population shows a considerable frequency of antineutrophil cytoplasmic antibodies in patients treated with methimazole but the clinical repercussion of these findings remains undefined.
id ABORL-F-1_1d397e5ac995c1ac5e5b505bad228d4c
oai_identifier_str oai:scielo:S1808-86942019000500636
network_acronym_str ABORL-F-1
network_name_str Brazilian Journal of Otorhinolaryngology
repository_id_str
spelling Antineutrophil cytoplasmic antibodies in patients treated with methimazole: a prospective Brazilian studyAntineutrophil cytoplasmic antibodiesMethimazoleVasculitisAbstract Introduction: The side effects of antithyroid drugs are well known. Antineutrophil cytoplasmic antibody-associated vasculitis is a severe adverse reaction. Most studies evaluating antineutrophil cytoplasmic antibodies related to antithyroid drugs have been carried out with patients treated with propylthiouracil, but less information is available for methimazole. Furthermore, most studies that investigated antineutrophil cytoplasmic antibodies related to antithyroid drugs were conducted on Asian populations. Objective: To evaluate the frequency of antineutrophil cytoplasmic antibodies and antineutrophil cytoplasmic antibodies-positive vasculitis in an adult population of Brazilian patients treated with methimazole. Methods: This was a prospective study. We evaluated patients ≥18 years with Graves’ disease who have been using methimazole for at least 6 months (Group A, n = 36); with Grave's disease who had been previously treated with methimazole but no longer used this medication for at least 6 months (Group B, n = 33), and with nodular disease who have been using methimazole for at least 6 months (Group C, n = 13). Results: ANCA were detected in 17 patients (20.7%). Four patients (4.9%) had a strong antineutrophil cytoplasmic antibodies-positive test. The frequency of antineutrophil cytoplasmic antibodies was similar in the groups. When Groups A and B were pooled and compared to Group C to evaluate the influence of Grave's disease, and when Groups A and C were pooled and compared to Group B to evaluate the influence of methimazole discontinuation, no difference was found in the frequency of antineutrophil cytoplasmic antibodies. No difference was observed in sex, age, etiology of hyperthyroidism, anti-TSH receptor antibodies, dose or time of methimazole use between patients with versus without antineutrophil cytoplasmic antibodies. The titers of these antibodies were not correlated with the dose or time of methimazole use. None of the antineutrophil cytoplasmic antibodies-positive patient had clinical event that could potentially result from vasculitis. Conclusion: This clinical study of a Brazilian population shows a considerable frequency of antineutrophil cytoplasmic antibodies in patients treated with methimazole but the clinical repercussion of these findings remains undefined.Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial.2019-10-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1808-86942019000500636Brazilian Journal of Otorhinolaryngology v.85 n.5 2019reponame:Brazilian Journal of Otorhinolaryngologyinstname:Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial (ABORL-CCF)instacron:ABORL-CCF10.1016/j.bjorl.2018.05.014info:eu-repo/semantics/openAccessAndrade,Gabriela CostaMaia,Flavia Coimbra PontesMourão,Gabriela FrancoRosario,Pedro WeslleyCalsolari,Maria Reginaeng2019-11-05T00:00:00Zoai:scielo:S1808-86942019000500636Revistahttp://www.bjorl.org.br/https://old.scielo.br/oai/scielo-oai.phprevista@aborlccf.org.br||revista@aborlccf.org.br1808-86861808-8686opendoar:2019-11-05T00:00Brazilian Journal of Otorhinolaryngology - Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial (ABORL-CCF)false
dc.title.none.fl_str_mv Antineutrophil cytoplasmic antibodies in patients treated with methimazole: a prospective Brazilian study
title Antineutrophil cytoplasmic antibodies in patients treated with methimazole: a prospective Brazilian study
spellingShingle Antineutrophil cytoplasmic antibodies in patients treated with methimazole: a prospective Brazilian study
Andrade,Gabriela Costa
Antineutrophil cytoplasmic antibodies
Methimazole
Vasculitis
title_short Antineutrophil cytoplasmic antibodies in patients treated with methimazole: a prospective Brazilian study
title_full Antineutrophil cytoplasmic antibodies in patients treated with methimazole: a prospective Brazilian study
title_fullStr Antineutrophil cytoplasmic antibodies in patients treated with methimazole: a prospective Brazilian study
title_full_unstemmed Antineutrophil cytoplasmic antibodies in patients treated with methimazole: a prospective Brazilian study
title_sort Antineutrophil cytoplasmic antibodies in patients treated with methimazole: a prospective Brazilian study
author Andrade,Gabriela Costa
author_facet Andrade,Gabriela Costa
Maia,Flavia Coimbra Pontes
Mourão,Gabriela Franco
Rosario,Pedro Weslley
Calsolari,Maria Regina
author_role author
author2 Maia,Flavia Coimbra Pontes
Mourão,Gabriela Franco
Rosario,Pedro Weslley
Calsolari,Maria Regina
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Andrade,Gabriela Costa
Maia,Flavia Coimbra Pontes
Mourão,Gabriela Franco
Rosario,Pedro Weslley
Calsolari,Maria Regina
dc.subject.por.fl_str_mv Antineutrophil cytoplasmic antibodies
Methimazole
Vasculitis
topic Antineutrophil cytoplasmic antibodies
Methimazole
Vasculitis
description Abstract Introduction: The side effects of antithyroid drugs are well known. Antineutrophil cytoplasmic antibody-associated vasculitis is a severe adverse reaction. Most studies evaluating antineutrophil cytoplasmic antibodies related to antithyroid drugs have been carried out with patients treated with propylthiouracil, but less information is available for methimazole. Furthermore, most studies that investigated antineutrophil cytoplasmic antibodies related to antithyroid drugs were conducted on Asian populations. Objective: To evaluate the frequency of antineutrophil cytoplasmic antibodies and antineutrophil cytoplasmic antibodies-positive vasculitis in an adult population of Brazilian patients treated with methimazole. Methods: This was a prospective study. We evaluated patients ≥18 years with Graves’ disease who have been using methimazole for at least 6 months (Group A, n = 36); with Grave's disease who had been previously treated with methimazole but no longer used this medication for at least 6 months (Group B, n = 33), and with nodular disease who have been using methimazole for at least 6 months (Group C, n = 13). Results: ANCA were detected in 17 patients (20.7%). Four patients (4.9%) had a strong antineutrophil cytoplasmic antibodies-positive test. The frequency of antineutrophil cytoplasmic antibodies was similar in the groups. When Groups A and B were pooled and compared to Group C to evaluate the influence of Grave's disease, and when Groups A and C were pooled and compared to Group B to evaluate the influence of methimazole discontinuation, no difference was found in the frequency of antineutrophil cytoplasmic antibodies. No difference was observed in sex, age, etiology of hyperthyroidism, anti-TSH receptor antibodies, dose or time of methimazole use between patients with versus without antineutrophil cytoplasmic antibodies. The titers of these antibodies were not correlated with the dose or time of methimazole use. None of the antineutrophil cytoplasmic antibodies-positive patient had clinical event that could potentially result from vasculitis. Conclusion: This clinical study of a Brazilian population shows a considerable frequency of antineutrophil cytoplasmic antibodies in patients treated with methimazole but the clinical repercussion of these findings remains undefined.
publishDate 2019
dc.date.none.fl_str_mv 2019-10-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1808-86942019000500636
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1808-86942019000500636
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1016/j.bjorl.2018.05.014
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial.
publisher.none.fl_str_mv Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial.
dc.source.none.fl_str_mv Brazilian Journal of Otorhinolaryngology v.85 n.5 2019
reponame:Brazilian Journal of Otorhinolaryngology
instname:Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial (ABORL-CCF)
instacron:ABORL-CCF
instname_str Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial (ABORL-CCF)
instacron_str ABORL-CCF
institution ABORL-CCF
reponame_str Brazilian Journal of Otorhinolaryngology
collection Brazilian Journal of Otorhinolaryngology
repository.name.fl_str_mv Brazilian Journal of Otorhinolaryngology - Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial (ABORL-CCF)
repository.mail.fl_str_mv revista@aborlccf.org.br||revista@aborlccf.org.br
_version_ 1754575993657360384